Success Stories: Postdoctoral Fellow in the Field of Biochemistry in California Receives EB-1A Approval in Less than Three Months

Client’s Testimonial:

Thank you so much for your help with my I-140. You guys are so great and I definitely will recommend you to my friends.


On January 23, 2014, A Postdoctoral Fellow in the Field of Biochemistry in California Received EB-1A (Alien of Extraordinary Ability) Approval, 2 Months, 23 Days After His Case Was Filed (Approval Notice)


 

General Field: Biochemistry

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

Service Center: Nebraska Service Center (NSC)

State of Residence at the Time of Filing:  California

Approval Notice Date: January 23, 2014

Processing Time:  2 Months, 23 Days


Case Summary:

We at North America Immigration Law Group – WeGreened.com represented a postdoctoral fellow in the field of Biochemistry. His work had primarily focused on the engineering of therapeutic peptides and proteins for the treatment of HIV/AIDS and cancer, as well as the engineering of activity-based probes and inhibitors that selectively target and inhibit proteases implicated in the development of life-threatening diseases. This work had resulted in 11 journal articles, 1 book chapter, and 9 first-authored conference presentations. In order to support his case, we provided evidence of his publications and the 128 citations to his work, in addition to evidence that he acted as a peer reviewer 21 times for 11 different biochemistry journals. An independent recommender for this case revealed: “I cannot overstate the importance of this work for the development of new, highly effective treatment options for patients suffering from cancer, Alzheimer’s disease, and a host of other illnesses. Because [Client’s] probe design allows the scientist to only block and track the protease activity relevant for disease development, scientists have an enhanced, refined comprehension of how individual proteases contribute to disease pathology. This will yield more efficacious drugs that slow the activity of these enzymes without altering the functionality of structurally similar yet useful proteases; patients will enjoy new medicines that hinder disease progression without causing debilitating side effects.” This EB1-A (Alien of Extraordinary Ability) petition received approval in 2 months, 23 days.